NCT03259581View on ClinicalTrials.gov

Safety of Transarterial Chemoembolization (TACE) in the Setting of an Elevated Bilirubin

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

January 2, 2018

Primary Completion Date

December 31, 2021

Study Completion Date

February 1, 2022

Conditions
Hepatocellular CarcinomaBilirubinemia
Interventions
COMBINATION_PRODUCT

Transarterial chemoembolization

Delivery of lipiodol, chemotherapy (Deoxyrubicin), and particles (embosphere particles) to the arteries feeding hepatocellular carcinoma. While both chemotherapy and particles are delivered this is a single procedure in which the chemotherapy is delivered followed immediately by particles.

Trial Locations (1)

55455

University of Minnesota, Minneapolis

All Listed Sponsors
lead

University of Minnesota

OTHER

NCT03259581 - Safety of Transarterial Chemoembolization (TACE) in the Setting of an Elevated Bilirubin | Biotech Hunter | Biotech Hunter